Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 16, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting
November 12, 2020 16:15 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
November 09, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting
November 05, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today...
Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 04, 2020 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management
November 03, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference
September 09, 2020 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
September 02, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance
August 26, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET
|
Harpoon Therapeutics
Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation Dosed first patient with HPN217 targeting BCMA for...